IL20RB

Across TCGA pan-cancer cohorts, IL20RB Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IL20RB data layer compared with 25 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher IL20RB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL20RB expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, ACC, and UCEC are the cancer types where IL20RB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.170	0.811	.001	24	view →
ACC	DFS	Median	All	0.046	0.753	<.001	24	view →
UCEC	DFS	Median	All	1.000	0.627	.016	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	All	0.323	0.834	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IL20RB–KIRC (OS)

Open the KIRC breakdown →